ABCC7 p.Cys832Ser
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 15272010
[PubMed]
Chen EY et al: "The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator."
No.
Sentence
Comment
57
The construction of Cys-less CFTR (C76S/C126S/C225S/C276S/C343S/C491S/C524S/C590S/C592S/C657S/C832S/C866S/C1344S/C1355S/C1395S/C1400S/C1410S/C1458S) was performed using the following cDNA fragments.
X
ABCC7 p.Cys832Ser 15272010:57:94
status: NEW58 Point mutations C76/126S were generated in sequence in the PstI (bp 1) 3 XbaI (bp 573) fragment; point mutations C225S/C276S/C343S were generated in sequence in the XbaI (bp 573) 3 KpnI (bp 1370) fragment; point mutations C491S/C524S/C590S/C592S/C657S were generated in sequence in the KpnI (bp 1370) 3 ApaI (bp 2333) fragment; point mutations C832S/C866S were generated in sequence in the ApaI (bp 2333) 3 EcoRI (bp 3643) fragment; point mutations C1344S/C1355S/ C1395S/C1400S/C1410S/C1458S were generated in sequence in the EcoRI (bp 3643) 3 XhoI (bp 4560) fragment, the five insert fragments were then ligated and inserted into the PstI and XhoI sites of plasmid vector pMT21.
X
ABCC7 p.Cys832Ser 15272010:58:344
status: NEW
PMID: 17036051
[PubMed]
Mense M et al: "In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer."
No.
Sentence
Comment
181
Primers for the mutations C76S, C276S and C832S are listed in Table I.
X
ABCC7 p.Cys832Ser 17036051:181:42
status: NEW199 For recording macroscopic currents of split CFTR channels in excised patches (Figure 10), oocytes were Table I Forward primers for site-directed mutagenesis PCR C76S 50 -GCCCTTCGGCGATcgTTTTTCTGGAG-30 C276S 50 -CTGTTAAGGCCTACTcCTGGGAAGAAGC-30 C832S 50 -CGAAGAAGACCTTAAGGAGTcCTTTTTTGATGATATGGAGAGC-30 EagI site 50 -GGTAAAATTAAGCACAGcGGccGAATTTCATTCTGTTCTC-30 HA epitope 50 -CGGGCCGCCATGtAcccatAcGACGttccgGAttAcgcaAGGTCGCCTCTGG-30 CFTR 16CS C590A/C592A 50 -GGAGATCTTCGAGAGCgCTGTCgCTAAACTGATGGC-30 CFTR 16CS C590F/C592F 50 -GGAGATCTTCGAGAGCTtTGTCTtTAAACTGATGGC-30 CFTR 16CS C590L/C592L 50 -GGAGATCTTCGAGAGCctTGTCctTAAACTGATGGC-30 CFTR 16CS C590T/C592T 50 -GGAGATCTTCGAGAGCaCTGTCaCTAAACTGATGGC-30 CFTR 16CS C590V/C592V 50 -GGAGATCTTCGAGAGCgtcGTCgtTAAACTGATGGC-30 S434C 50 -CCTCTTCTTCAGTAATTTCTgtCTaCTTGGTACTCCTGTC-30 S459C 50 -GTTGGCGGTTGCTGGATgCACTGGAGCAGGCAAG-3 A462C 50 -GCTGGATCCACTGGGtgcGGCAAGACTTCACTTC-30 L549C 50 -GGTGGAATCACACtatGcGGAGGTCAACGAGCACG-30 S605C 50 -GGATTTTGGTCACaTgTAAAATGGAAC-30 S1248C 50 -CCTCTTGGGAAGAACCGGtTgtGGGAAGAGTAC-30 D1336C 50 -GTTTCCTGGGAAGCTTtgCTTTGTCCTTGTGG-30 L1346C 50 -GGATGGGGGCTCTGTCTgtAGTCATGGCCACAAGC-30 A1374C 50 -GATGAACCAAGCtgTCATTTAGATCC-30 V1379C 50 -GCTCATTTAGATCCgtgcACATACCAAATAATTCG-30 The underlined bases are the codons for the introduced serines, cysteines or other residues; lowercase letters mark base changes from the original sequence, including those for introducing diagnostic restriction endonuclease sites.
X
ABCC7 p.Cys832Ser 17036051:199:242
status: NEW
PMID: 19754156
[PubMed]
Alexander C et al: "Cystic fibrosis transmembrane conductance regulator: using differential reactivity toward channel-permeant and channel-impermeant thiol-reactive probes to test a molecular model for the pore."
No.
Sentence
Comment
42
The Cys-less CFTR construct (C76S, C126S, C225S, C276S, C343S, C491S, C524S, C590L, C592L, C657S, C832S, C866S, C1344S, C1355S, C1395S, C1400S, C1410S, C1458S) was a gift from Drs. Martin Mense and David Gadsby and was used in their pGEMHE vector previously described (13).
X
ABCC7 p.Cys832Ser 19754156:42:98
status: NEW
PMID: 16766608
[PubMed]
Serrano JR et al: "CFTR: Ligand exchange between a permeant anion ([Au(CN)2]-) and an engineered cysteine (T338C) blocks the pore."
No.
Sentence
Comment
23
MATERIALS AND METHODS Mutagenesis and in vitro transcription The Cys-less CFTR construct (C76S, C126S, C225S, C276S, C343S, C491S, C524S, C590L, C592L, C657S, C832S, C866S, C1344S, C1355S, C1395S, C1400S, C1410S, C1458S) was a gift from Drs. Martin Mense and Submitted December 28, 2005, and accepted for publication May 19, 2006.
X
ABCC7 p.Cys832Ser 16766608:23:159
status: NEW
PMID: 25825169
[PubMed]
Chaves LA et al: "Cysteine accessibility probes timing and extent of NBD separation along the dimer interface in gating CFTR channels."
No.
Sentence
Comment
73
Fig. S2 shows tests of MTSET+ , MTSACE, and MTSES&#e032; effects on ATP-activated currents of background (C832S-C1458S) or C832S CFTR channels lacking any target cysteine.
X
ABCC7 p.Cys832Ser 25825169:73:106
status: NEWX
ABCC7 p.Cys832Ser 25825169:73:123
status: NEW74 Fig. S3 shows the action of MTSET+ on the S549C target in the C832S background (missing only a single native cysteine) for comparison with the (C832S-C1458S) background.
X
ABCC7 p.Cys832Ser 25825169:74:62
status: NEWX
ABCC7 p.Cys832Ser 25825169:74:144
status: NEW76 Fig. S5 shows that MTS-glucose, MTS-rhodamine, and MTS-biotin do not affect background (C832S-C1458S) CFTR channels.
X
ABCC7 p.Cys832Ser 25825169:76:88
status: NEW79 R E S U L T S Targeting S549C in the NBD1 tail, in the catalytically competent site, of CFTR channels opening and closing in ATP S549 in the LSGGQ sequence of the NBD1 tail contributes to CFTR`s catalytically competent composite site M A T E R I A L S A N D M E T H O D S Molecular biology The full-length human pGEMHE-CFTR (C832S-C1458S) construct, in which all eight C-terminal cysteines (C832, C866, C1344, C1355, C1395, C1400, C1410, and C1458 out of CFTR`s 18 native cysteines) were replaced by serine, was generated by de novo PCR gene synthesis combined with site-directed mutagenesis (Mense et al., 2006).
X
ABCC7 p.Cys832Ser 25825169:79:325
status: NEW81 Point mutations in the pGEMHE-wild-type template (Chan et al., 2000) yielded C832S and S549C-C832S constructs (Figs. S2 B and S3).
X
ABCC7 p.Cys832Ser 25825169:81:77
status: NEWX
ABCC7 p.Cys832Ser 25825169:81:93
status: NEW95 MTS reagents (Toronto Research Chemicals) and avidin (Thermo Fisher Scientific) were (Fig. S2 A) by much higher concentrations of MTSET+ or of the similarly sized MTS reagents, negatively charged MTSES&#e032; , or neutral MTSACE; in these control (C832S-C1458S) CFTR channels, all eight native cysteines in the C-terminal half of CFTR have been replaced by serines, but all 10 native N-terminal cysteines remain (compare Mense et al., 2006).
X
ABCC7 p.Cys832Ser 25825169:95:251
status: NEW99 To assess accessibility of introduced S549C, we applied the small hydrophilic, sulfhydryl-specific MTS reagent MTSET+ (50 &#b5;M; Fig. 3 A) to S549C- (C832S-C1458S) CFTR channels opening and closing in inside-out patches exposed to 3 mM MgATP (Fig. 3 A).
X
ABCC7 p.Cys832Ser 25825169:99:151
status: NEW101 The current decay reflects modification of the introduced cysteine because background (C832S-C1458S) CFTR channels, lacking the engineered target cysteine, are little affected Figure 2.ߓ Size comparison of MTS reagents, nucleotides, NEM, and MTS-biotin-avidin complex, shown as CPK-colored spheres, except for AMPPNP (yellow spheres; from TM287/288 structure; PDB accession no. 3QF4) and avidin tetramer (orange ribbon).
X
ABCC7 p.Cys832Ser 25825169:101:87
status: NEW131 To confirm that this rapid MTSET+ modification of S549C CFTR channels did not depend on the eight C-terminal cysteine-to-serine mutations, we tested modification of S549C CFTR that otherwise differed from wild-type by only the single mutation C832S needed to render CFTR unresponsive to NEM (Cotten and Welsh, 1997).
X
ABCC7 p.Cys832Ser 25825169:131:243
status: NEW132 The current decline on modification of S549C-C832S CFTR by MTSET+ in 3 mM ATP (Fig. S3, red fit lines) was as rapid as that of S549C-(C832S-C1458S) CFTR (Fig. 3, A and C), and it similarly matched the time course of current decay on ATP washout (Fig. S3, gray fit line).
X
ABCC7 p.Cys832Ser 25825169:132:45
status: NEWX
ABCC7 p.Cys832Ser 25825169:132:134
status: NEW133 However, because (C832S) background CFTR channels were slowly modified by MTSES&#e032; and MTSACE (Fig. S2 B), unlike (C832S-C1458S) background CFTR channels, which were insensitive to these reagents (Fig. S2 A), (C832S-C1458S) channels were adopted as the background for cysteine targets for the rest of this work.
X
ABCC7 p.Cys832Ser 25825169:133:18
status: NEWX
ABCC7 p.Cys832Ser 25825169:133:119
status: NEWX
ABCC7 p.Cys832Ser 25825169:133:214
status: NEW192 Control measurements with 50-&#b5;M applications of each of these larger MTS reagents confirmed that (like the smaller reagents; Fig. S2 A) they did not affect background (C832S-C1458S) CFTR channels with no added target cysteines (Fig. S5).
X
ABCC7 p.Cys832Ser 25825169:192:172
status: NEW241 (A) S605C-(C832S-C1458S) CFTR channels were activated by 3 mM ATP (black bars below records) and modified by 1 mM MTSET+ (red bar).
X
ABCC7 p.Cys832Ser 25825169:241:11
status: NEW261 (A and B) A1374C-(C832S-C1458S) CFTR channels were modified by 1 mM MTSET+ (red trace bar) either while closed in the absence of ATP (A), as assessed by subsequent diminished ATP-activated current (3 mM, black bars below records), or in the presence of ATP (B).
X
ABCC7 p.Cys832Ser 25825169:261:18
status: NEW287 As Po of Cys-free (16CS + C590V/C592V) CFTR was approximately twofold larger (Mense et al., 2006) than that of wild-type CFTR, which is &#e07a;0.1 under these conditions (Csan&#e1;dy et al., 2000; Vergani et al., 2003), if Po of these S549C- (C832S-C1458S) CFTR channels lies between these values, then our second-order rate constant estimate should be increased by up to 25%.
X
ABCC7 p.Cys832Ser 25825169:287:243
status: NEW300 The cysteine-depleted (C832S-C1458S) CFTR used as the background construct here lacks only eight native cysteines (via eight conservative Cys-Ser substitutions, from C832S to C1458S) and is the full-length (concatenated) version of the split CFTR (coexpressed halves) into which cysteine target pairs were introduced for cross-linking studies to define CFTR`s NBD1-NBD2 interface (Mense et al., 2006).
X
ABCC7 p.Cys832Ser 25825169:300:23
status: NEWX
ABCC7 p.Cys832Ser 25825169:300:166
status: NEW302 Further evidence that the isosteric replacement of eight native cysteines little affected the results is the fact that our findings with the S549C target mutation in NBD1 (Fig. 3 A) were reproduced in an almost native background CFTR (C832S) lacking only 1 of the 18 cysteines (Fig. S3); likewise, NEM was found to rapidly modify both S549C and S1347C targets introduced into that same C832S CFTR background (Cotten and Welsh, 1998).
X
ABCC7 p.Cys832Ser 25825169:302:235
status: NEWX
ABCC7 p.Cys832Ser 25825169:302:386
status: NEW310 They studied S549C-C832S CFTR (compare Fig. S3) and S1347C-C832S CFTR channels, at 35&#b0;C, in patches excised from HeLa cells, and found modification of S1347C "slightly slower" than that of S549C, but nevertheless concluded that the signature sequence lies in a "solvent-exposed position" and "at the protein surface" (Cotten and Welsh, 1998).
X
ABCC7 p.Cys832Ser 25825169:310:19
status: NEWX
ABCC7 p.Cys832Ser 25825169:310:59
status: NEW329 Consistent with these small effects, the mean time constant of current decay on ATP withdrawal, a measure of open burst duration, averaged 1.0 &#b1; 0.1 s (n = 19) for our background (C832S-C1458S) CFTR channels (e.g., Fig. S2 A), and was unaltered after insertion of the dead-site signature-sequence target cysteine, S1347C (1.0 &#b1; 0.1 s; n = 22), but was somewhat slowed by the corresponding cysteine in the live site, S549C (2.2 &#b1; 0.2 s; n = 24).
X
ABCC7 p.Cys832Ser 25825169:329:184
status: NEW331 That closure of (C832S-C1458S) channels containing S1347C or S549C target cysteines is indeed rate-limited by ATP hydrolysis (like wild type) is confirmed by the order of magnitude slowing of closure caused by the addition of the hydrolysis-impairing K1250R mutation (Figs. 7 and S4).
X
ABCC7 p.Cys832Ser 25825169:331:17
status: NEW332 Moreover, the &#e07a;15-s time constants for nonhydrolytic closure of those S1347C-K1250R-(C832S-C1458S) and S549C-K1250R-(C832S-C1458S) channels upon ATP washout are no shorter than those, 6-9 s, of K1250R CFTR channels bearing no other mutation (Vergani et al., 2005; Csan&#e1;dy et al., 2006; Szollosi et al., 2010, 2011).
X
ABCC7 p.Cys832Ser 25825169:332:91
status: NEWX
ABCC7 p.Cys832Ser 25825169:332:123
status: NEW